PUMA BIOTECHNOLOGY INC (PBYI): Investment Research & Business Outlook
A research-led explanation of the company, its financial evidence, valuation context and risks—not just a list of market numbers.
What the available evidence tells us
The latest stored quote for PUMA BIOTECHNOLOGY INC (PBYI) is 10.21, timestamped 10/19/2026, 4:00:00 AM. A quote is a point-in-time observation; it does not, by itself, explain why the price moved or establish whether the shares are attractive.
Business and financial quality
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Stored fundamentals include 32 usable headline metrics. These should be read across several reporting periods and compared with peers before drawing a conclusion about business quality.
Valuation: context matters
The stored trailing P/E ratio is 61.38. P/E compares a company’s share price with its earnings, but it should be interpreted alongside expected growth, earnings quality, cyclicality and comparable companies.
Price trend and quantitative outlook
The chart is based on 250 stored daily price observations. Historical performance describes what happened over that period; it is not a guarantee of future returns. The current stored quantitative model signal is “neutral”. Treat model outputs as scenarios with uncertainty, not as certain targets or personalized advice.
Key risks and what to watch next
Risk records exist for this company; review the risk and performance section below for the available volatility, drawdown and risk-adjusted measures. The next useful evidence to review is the company’s next reported financial results, changes in forward estimates, and primary-source disclosures.
Editorial integrity: this summary uses fields available in the current database. Missing evidence is called out rather than filled with invented facts.
What the numbers mean for investors
Reported revenue growth is +7.75%. Growth is encouraging, but investors should confirm it is recurring and understand what product, geography or customer group is driving it.
Gross margin is +0.00% and operating margin is +13.42%. The gap helps show how much operating costs absorb after direct costs; compare the trend with prior periods and sector peers.
The stored P/E is 61.38. A multiple is not a verdict by itself: interpret it alongside expected earnings growth, cyclicality, cash flow, and comparable companies.
The latest quote can be compared with the 20-, 50- and 200-day moving averages (9.90, 9.48, and 7.70). Moving averages describe trend, not intrinsic value, and can lag sudden market changes.
Bull case, bear case and evidence to watch
The bullish case needs confirmation from reported revenue growth, cash generation, and future company disclosures; the current snapshot does not establish those conditions together.
The stored P/E of 61.38 means expectations matter: a slowdown, weaker margins or downward earnings revisions could pressure the valuation.
Track the next earnings release, changes in revenue and margin trends, cash flow, management guidance, analyst estimate revisions, and primary-source filings. Update the thesis when new evidence arrives rather than relying on one ratio or forecast.
These interpretations are rule-based explanations of the stored fields, not independently verified company-specific forecasts. Missing data is not treated as zero; all investment cases remain conditional on new evidence.